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Abstract 
Aim Acanthamoeba infections are characterized by an intense localized innate immune 
response associated with an influx of macrophages. Acanthamoeba protease production is 
known to affect virulence. Herein, the ability of Acanthamoeba trophozoite proteases, of 
either the laboratory Neff strain, or a recently isolated clinical strain, to stimulate IL-12 and 
IL-6 and to activate protease-activated receptors, PAR1 and PAR2 expressed on murine 
macrophages, was investigated.  
Method and Results Using selected protease inhibitors, leupeptin and E64, we showed that 
Acanthamoeba proteases can stimulate IL-12 and IL-6 by murine macrophages. 
Subsequently, using specific antagonists to inhibit PAR1, and bone-marrow derived 
macrophages from PAR2 gene deficient mice, we demonstrate that PAR1, but not PAR2 
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contributes to macrophage IL-12 production in response to Acanthamoeba. In contrast, 
Acanthamoeba-induced IL-6 production is PAR1 and PAR2 independent. 
Conclusion This study shows for the first time the involvement of PARs, expressed on 
macrophages, in the response to Acanthamoeba trophozoites and might provide useful insight 
into Acanthamoeba infections and their future treatments. 
 
Keywords 
Acanthamoeba; Macrophages; Cytokines; Proteases; Protease-Activated Receptors; PAR1; 
PAR2. 
 
1. Introduction 
Acanthamoeba castellanii is a facultative parasitic free-living amoeba known to be the agent 
of a serious, painful and potentially blinding keratitis, named Acanthamoeba keratitis (AK), 
as well as usually fatal encephalitis, named granulomatous amoebic encephalitis (GAE). 
Immunocompromised individuals are susceptible to the deadly brain infection, whereas AK 
can occur in immune-competent individuals, and especially contact lens (CL) wearers
(1)
. 
Among the 20 identified Acanthamoeba genotypes, A. castellanii T4 is the most common 
genotype in the environment and the most often associated with AK and non-AK infections 
as it is frequently isolated from the site of infections
(2)
. This has been attributed to its wide 
distribution in nature as well as in indoor environments, identified virulence factors, and its 
relative resistance to drugs and disinfectants
(2)
. 
The release of proteases by Acanthamoeba spp. has been associated with virulence
(3,4)
. After 
binding mammalian cells, Acanthamoeba releases proteases that enhance the penetration of 
the amoeba into the deeper layers of the host tissue
(5)
. As proteases are of major importance 
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in the pathogenic process, the pattern of their secretion is commonly used to discriminate 
between pathogenic and non-pathogenic strains of Acanthamoeba
(6)
.  
Protease-activated receptors (PARs) are trans-membrane domain G-protein-coupled receptors 
activated by the proteolytic activity of endogenous and exogenous proteases
(7)
. PARs are 
expressed in a ubiquitous manner in various immune, as well as non-immune cells, and have 
a wide range of physiological functions associated with the maintenance of tissue integrity, as 
well as with inflammatory and immunological responses
(8)
. Interestingly, PARs, especially 
PAR1 and PAR2, are expressed on human corneal epithelial (HCE) cells, predominantly in 
the outer cell layers of the corneal epithelium, and their activation leads to production of pro-
inflammatory cytokines, as well as wound healing processes
(9)
. Consequently, the role of 
innate immune receptors in Acanthamoeba recognition and response at the ocular surface has 
been an area of recent interest and it has been demonstrated that Acanthamoeba plasminogen 
activator factor stimulates, in HCE cells, the production of IL-8 in a PAR2 dependent, but 
PAR1 independent manner
(10)
. Once Acanthamoeba trophozoites reach the deepest layers of 
the tissues, macrophages as well as neutrophils are the predominant cell types present at the 
site of infection
(11)
, where they are found alongside trophozoites and cyst forms. 
Macrophages are therefore considered the major cells involved in Acanthamoeba clearance
(6)
. 
Although macrophages are heavily recruited during the development of both GAE and AK, 
little is known about how Acanthamoeba influences macrophage function. Our recent studies 
have demonstrated the role of TLR4, MyD88 dependent events in the activation of murine 
macrophages
(12)
. The potential role of proteases released by Acanthamoeba, and their 
interaction with PARs expressed by macrophages have not until now been reported. 
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2. Materials and Methods 
2.1 Acanthamoeba strains 
In this study we examined the effects of co-cultivation of trophozoites of either a laboratory 
strain of Acanthamoeba (Neff), isolated from soil over 60 years ago, and kindly donated by 
the late Prof. Keith Vickerman (University of Glasgow, United Kingdom), or a clinical 
isolate (clinical) of Acanthamoeba with murine bone marrow-derived macrophages 
(MBDM). Both Acanthamoeba strains are of the T4 genotype
(13)
. Trophozoites of either 
strain were maintained in culture and prepared for the co-incubation experiments as 
previously reported
(12)
. 
 
2.2 Ethical background 
All animal care and experimental procedures were conducted in accordance with relevant 
guidelines and regulations with the approval of the University of Strathclyde Animal Welfare 
and Ethical Review Body (AWERB), under UK Home Office regulations (Animals 
(Scientific Procedures) Act 1986.  Animals were housed according to or above the standard 
of the Home Office Code of Practice for the housing and care of animals bred, supplied or 
used for scientific purposes. They had nesting material, huts and chew sticks placed in the 
cages. The GA mice were bred under PPL 70/8369 and have no clinical phenotype.  The 
Appendix D Schedule 1 procedure, 'dislocation of the neck’. was used to sacrifice the animals 
to obtain tissue. This was followed by a confirmation method. 
(https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_dat
a/file/662364/Guidance_on_the_Operation_of_ASPA.pdf).  The procedure was undertaken 
by a trained person. The name of the staff member performing the performing the Sch1 is 
held locally on a register of competent people. 
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2.3 Inhibition of secreted amoebic proteases 
In order to investigate the role of Acanthamoeba secreted proteases in influencing 
trophozoite-induced macrophage cytokine production, MBDM were obtained from the 
femurs of 7-weeks-old male BALB/c mice as previously reported
(14)
, and subsequently 
treated, prior to infection, with either leupeptin (Sigma Chemical Co, Poole, UK), a serine 
and cysteine proteases inhibitor, or E64 (Sigma Chemical Co, Poole, UK) that selectively 
inhibits cysteine proteases. The choice of these two protease inhibitors relied on the specific 
composition of the Acanthamoeba secretome that mainly comprises serine and cysteine 
proteases
(15)
. Macrophages in complete RPMI (cRPMI) were considered the negative 
inhibitor control. Immediately after addition of protease inhibitors, macrophage cultures were 
incubated with either Neff or the clinical isolate trophozoites (ratio 1:1). IL-12 and IL-6 
production was evaluated after 24 h, by Enzyme Linked Immunosorbent Assay (ELISA). 
2.4 Infection of C57BL/6 macrophages with A. castellanii trophozoites 
The study was performed using C57BL/6 wild-type mice and C57BL/6 mice deficient for the 
PAR2 gene. MBDM were obtained from both mouse strains and co-incubated with either Neff 
or the clinical isolate trophozoites at a ratio of 1:1. In addition, macrophages were stimulated 
with LPS as a control for their ability to produce IL-12 and IL-6. 
2.5 Inhibition of PAR1 using RWJ 56110 synthetic antagonist 
PAR1
-/-
 mice were not available to perform this study, and therefore RWJ 56110 (Tocris 
Bioscience, Bristol, UK), a synthetic selective antagonist, for PAR1, was used to block the 
receptor activity. This synthetic compound can directly bind to PAR1 blocking its activation 
and internalization without interfering with the cleavage of the N-terminus of the 
receptor
(16,17)
. MBDM, obtained from the femur of 7 weeks old BALB/c mice, were either 
pre-treated with RWJ 56110 or left untreated as controls. Subsequently, macrophages were 
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stimulated with LPS or co-cultured with Acanthamoeba Neff strain or clinical isolate 
trophozoites at a ratio of 1:1. In addition, in order to evaluate the intrinsic activity of the 
antagonist, unstimulated macrophages pre-treated with RWJ 56110 were included in the 
experimental design. IL-12 and IL-6 production was evaluated at 24 h, by ELISA. 
 
3. Results 
3.1 A. castellanii-secreted proteases stimulate the production of pro-inflammatory cytokines by 
MBDM. 
IL-12 production by macrophages was induced by co-culture with both Neff and clinical 
isolate trophozoites in the absence of protease inhibitors. In contrast, IL-12 production was 
significantly reduced when leupeptin was present in the co-culture with both Neff (p<0.005) 
and the clinical isolate (p<0.005) trophozoites. Similarly, macrophage IL-12 production was 
significantly lower after challenge with either Neff (p<0.005) or the clinical isolate 
(p<0.0005) trophozoites when macrophages were treated with E64, in comparison with the 
control cultures lacking the inhibitor (Fig 1-A). Both Neff and the clinical isolate trophozoites 
induced IL-6 production by murine macrophages in the absence of proteases inhibitors (0.583 
ng/ml and 0.216 ng/ml, respectively). IL-6 levels were significantly reduced in leupeptin-
treated macrophages challenged with Neff or the clinical isolate trophozoites (p<0.0005). 
Treatment of cultures with E64 also induced a significant reduction in the levels of IL-6 
produced by macrophages after challenge with either Neff (0.388 ng/ml, p<0.0005) or the 
clinical isolate (0.149 ng/ml p<0.005) trophozoites. Furthermore, a difference in IL-6 
production was found between the protease inhibitors in macrophage cultures incubated with 
Neff trophozoites; leupeptin (0.303 ng/ml) was more efficient at inhibiting IL-6 than E64 
(p<0.005). This difference in macrophage IL-6 production was not demonstrated following 
incubation with the clinical isolate trophozoites (Fig 1-B). Neither of the inhibitors 
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significantly influenced LPS induced macrophage IL-12 or IL-6 production indicating that 
their activities were targeting trophozoite protease activity specifically (Fig 1-A and B). 
3.2 Acanthamoeba-induced IL-12 and IL-6 production by murine macrophages is PAR2-
independent 
After demonstrating that amoebic serine and cysteine proteases could stimulate IL-12 and IL-
6 production by murine macrophages, we investigated if PARs were involved in this event. 
PAR2 was considered a potential target for our investigation, since it is an extracellular 
receptor widely expressed on immune cells and involved in inflammatory and immunological 
processes
(18)
. Both IL-6 and IL-12 production by PAR2
-/- 
macrophages co-incubated with 
trophozoites of either Neff strain or the clinical were similar to that produced by WT 
macrophages (Fig 2). 
3.3 A. castellanii clinical strain induces IL-12 production by murine macrophages in a PAR1-
dependent manner. 
In the absence of evidence of PAR2-dependent activation of macrophages by Acanthamoeba, 
further investigations were undertaken to determine whether PAR1 was involved. Similar to 
PAR2, PAR1 is an extracellular receptor widely expressed on immune cells and involved in 
inflammatory and immunological processes
(18)
. As expected pre-treatment with RWJ 56110 
did not induce either IL-12 or IL-6 production by murine macrophages (Fig 3-A, B). 
Stimulation of macrophages with LPS induced IL-12 and IL-6 production and this was 
significantly diminished by pre-treatment with RWJ 56110 (p<0.05) (Fig 3-A, B). Pre-
treatment of macrophages with RWJ 56110 significantly reduced IL-12 production in 
response to the clinical isolate trophozoites compared with control macrophages (p<0.05); 
however, it did not significantly reduce Neff trophozoite-induced IL-12 production (Fig 3-A). 
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Pre-treatment of macrophages with RWJ 56110 did not modify the Acanthamoeba-induced 
IL-6 production (Fig 3-B). 
 
4. Discussion 
During parasitic infections proteases are known to be important virulence factors and to be 
involved in cell differentiation, tissue penetration, nutrient acquisition and immune evasion 
mechanisms
(19)
. The importance of Acanthamoeba proteases in pathogenicity
(4,20,21)
, immune 
evasion
(22)
 and differentiation mechanisms
(23)
 has been widely discussed. However, more 
recently, studies have focused their attention on the role of these molecules in triggering the 
immune response. Indeed, it has been demonstrated that the amoebic serine protease MIP-
133, is not only involved in the invasion of the trophozoites within the host tissue, but also in 
stimulating pro-inflammatory cytokine production by HCE cell line, via the cytosolic 
phospholipase A2α
(24)
. Our study demonstrates, for the first time, that both serine and cysteine 
amoebic proteases were capable of inducing IL-12 and IL-6 production by murine 
macrophages. Trophozoite-induced macrophage IL-12 production was inhibited equally 
when either leupeptin (serine and cysteine proteases inhibitor) or E64 (selective cysteine 
proteases inhibitor) were present, suggesting that IL-12 was equally stimulated by serine and 
cysteine proteases. Macrophage IL-6 production induced by either Neff or clinical 
trophozoite decreased in the presence of either inhibitor. However, during Neff strain 
infection of macrophages, leupeptin was more effective than E64 in inhibiting IL-6 
production, indicating that serine proteases might be the major protease responsible for 
inducing this cytokine. By using PAR2 deficient macrophages, we found that Acanthamoeba-
induced IL-12 and IL-6 production was PAR2-independent. On the other hand, 
Acanthamoeba-induced IL-12 production by macrophages was shown to be induced through 
PAR1-dependent mechanisms. Interestingly, a very recent study has reported that 
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Acanthamoeba plasminogen activator factor stimulates IL-8 production by human corneal 
epithelial cells in a PAR2-dependent manner
(10)
. Furthermore, it has been demonstrated, by 
using an in vivo murine model, that Acanthamoeba trophozoites and their excreted/secreted 
molecules stimulate allergic responses and induce TH2 responses through the activation of 
dendritic cells in a PAR2-dependent manner
(25)
. Our study has demonstrated a different 
activation pattern of PARs expressed on murine macrophages, by Acanthamoeba, in 
comparison with what has been observed in murine dendritic cells and human corneal 
epithelial cells
(10)
. Importantly, the studies reported herein demonstrate that pre-treatment of 
macrophages with specific PAR1 antagonist significantly inhibits, but does not eliminate IL-
12 production: this would be consistent with our recently published data also demonstrating a 
role for TLR4, MyD88-dependent mechanisms in IL-12 production. Collectively these 
studies might suggest a potential cross-talk between receptors either directly (receptor 
association) or indirectly (at signalling level). Examples of TLRs-PARs cross-talk, especially 
involving PAR2, have been reported and known to be associated with bacterial, viral and 
fungal infections, but not as yet during protozoan infections 
(26)
. Consequently, the present 
study suggests previously unobserved interactions between PARs and TLRs during 
Acanthamoeba infections that influence cytokine production by macrophages, although more 
investigations are needed to elucidate these interactions.  
In conclusion, the current study demonstrates for the first time a contribution of 
Acanthamoeba serine and cysteine proteases and host PAR1 in macrophage activation and 
inflammatory responses. Such knowledge might ultimately provide insight into the 
pathogenesis of Acanthamoeba induced-diseases and their treatments. 
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Figure Legends 
Fig 1. Release of macrophage IL-12 (A) and IL-6 (B) at 24 h after treatment with 
protease inhibitors prior to co-incubation with A. castellanii trophozoites. 1x10
6
 
murine macrophages, obtained from BALB/c mice, were infected with 1x10
6 
trophozoites of 
either A. castellanii Neff (Neff) or clinical (Clinical) in three different experimental 
conditions: in cRPMI (- Inh), in cRMPI supplemented with leupeptin 50 μM (+ Leu) and in 
cRPMI supplemented with E64 10 μM (+ E64). LPS, at a concentration of 200 ng/ml (LPS) 
was included as positive control, whereas uninfected macrophages (Control) consisted of the 
negative control. The experiment was repeated twice. Results represent the mean ± standard 
error of n=3. One-way ANOVA was applied and Tukey’s multiple comparison test was 
performed to evaluate differences within the three different conditions means. In the graphs, 
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significant differences within each condition are indicated as follows: for values of p<0.005 
**; p<0.0005 ***. Values below the detectable levels are indicated in the graphs as ND (not 
detected). Note that Acanthamoeba-induced macrophage production of IL-6 and IL-12 is 
significantly inhibited in the presence of serine and cysteine proteases. This inhibition is 
observed in both the infection with either Neff or clinical trophozoites.  
 
Fig 2. Release of macrophage IL-12 (A and B), and IL-6 (C and D): comparison 
between C57BL/6 WT (A and C) and C57BL/6 PAR2
-/-
 (B and D) macrophages at 24 
h after co-incubation with Acanthamoeba trophozoites. 1x10
6
 murine macrophages, 
obtained from C57BL/6 WT and PAR2
-/-
mice, were challenged with 1x10
6 
trophozoites of 
either A. castellanii Neff (Neff) or clinical isolate (Clinical). LPS at 200 ng/ml (LPS) was 
also included in the experimental design as positive control. Uninfected macrophages 
(Control) were considered the negative control. The experiment was performed twice. Results 
represent the mean ± standard error of n=3. Mann-Whitney U test was applied to evaluate 
differences between C57BL76 WT and C57BL/6 PAR2
-/-
 conditions. Macrophages derived 
from C57BL/6 PAR2
-/-
did not show reduced IL-12 or IL-6 production, relative to 
macrophages derived from wild-type mice, when co-incubated with trophozoites. Thus, the 
production of these pro-inflammatory cytokines by macrophages, in response to 
Acanthamoeba, is not PAR2-dependent. 
 
Fig 3. IL-12 (A), and IL-6 (B) production by murine macrophages, pre-treated with 
the PAR1 antagonist RWJ 56110, after 24 h co-incubation with Acanthamoeba. 1x10
6
 
murine macrophages, obtained from BALB/c mice, were pre-treated with 20 μM RWJ 56110 
solution (+ RWJ56110) or not pre-treated (- RWJ56110). Macrophages were incubated for 10 
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min at 37° 5% CO2. Subsequently, macrophages were stimulated with LPS at a concentration 
of 200 ng/ml (LPS). Unstimulated macrophages, treated or not treated with RWJ 56110, were 
included in the experimental design (Control). The experiment was performed twice. Results 
represent the mean ± standard error of n=3. Student’s t-test was applied to evaluate 
differences between – RWJ56110 and + RWJ56110 conditions. In the graphs, significances 
between – RWJ56110 and + RWJ56110 conditions are indicated as follow: for values of 
p<0.05 *. Values below the detectable levels are indicated in the graphs as ND (not detected). 
Data shown in the graphs indicate that IL-12 production by murine macrophages induced by 
clinical isolate trophozoites is at least in part PAR1-dependent, although it does not appear to 
be the main receptor involved in this event. 
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